

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): June 9, 2015**

---

**LANTHEUS MEDICAL IMAGING, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**333-169785**  
(Commission  
File Number)

**51-0396366**  
(IRS Employer  
Identification No.)

**331 Treble Cove Road, North Billerica, MA 01862**  
(Address of principal executive offices) (Zip code)

**Registrant's telephone number, including area code: (978) 671-8001**

**Not Applicable**  
(Former name or former address, if changed since last report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 7.01 Regulation FD Disclosure.**

On June 9, 2015, the registrant, Lantheus Medical Imaging, Inc. (the “Company”) commenced the marketing process for a proposed new senior secured term loan facility in an amount of up to \$365.0 million with Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent. The net proceeds of the new term facility, together with cash on hand and the net proceeds of a proposed initial public offering of common stock of the Company’s parent company, would be used to redeem in full the Company’s outstanding \$400.0 million aggregate principal amount of 9.750% Senior Notes due 2017, to repay amounts outstanding under its revolving credit facility and to pay related premiums, interest and expenses. The consummation of the new term loan facility will be conditioned upon the closing of the initial public offering. There can be no assurance that the Company will enter into the new credit facility or that the initial public offering will occur.

The information in this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

None.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LANTHEUS MEDICAL IMAGING, INC.

By: /s/ Michael P. Duffy

Name: Michael P. Duffy

Title: Vice President and General Counsel

Date: June 9, 2015